The Utility of Platelet Rich Plasma in Hair Loss
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03376581 |
Recruitment Status :
Completed
First Posted : December 18, 2017
Last Update Posted : February 22, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation.
The purpose of this research is to investigate the potential of PRP injection for treatment of hair loss. Clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical Doppler tomography and multispectral imaging.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Androgenetic Alopecia | Procedure: Platelet rich plasma | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Utility of Platelet Rich Plasma in Hair Loss |
Actual Study Start Date : | November 28, 2017 |
Actual Primary Completion Date : | February 20, 2019 |
Actual Study Completion Date : | February 20, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Prospective treatment |
Procedure: Platelet rich plasma
Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp. |
- Hair density to measure the efficacy of treatment [ Time Frame: 6 months ]
- Hair count (number of hairs/0.65 cm2) [ Time Frame: 6 months ]
- Terminal hair density [ Time Frame: 6 months ]
- Anagen hair percentage [ Time Frame: 6 months ]
- Telogen hair percentage [ Time Frame: 6 months ]
- Anagen/telogen ratio [ Time Frame: After 3 and 6 months ]
- Changes in hair structure, diameter, and blood flow [ Time Frame: 6 months ]As measured by optical coherence tomography

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 95 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Over 18 years of age
- Ability to understand and carry out instructions
- Diagnosed with alopecia
Exclusion Criteria:
- Inability to understand and.or carry out instructions
- Pregnant women
- Use of any topical medication (such as minoxidil or any other solution for hair growth), oral medication (finasteride, dutasteride, or antiandrogens), laser therapy, or chemotherapy, within the preceding 4 weeks.
- Personal medical history of bleeding disorders
- Personal medical history of platelet dysfunction syndrome
- Anti-coagulation therapy or nonsteroidal anti-inflammatory drugs in the last 1 week.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376581
United States, California | |
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Hewitt Hall | |
Irvine, California, United States, 92697 |
Responsible Party: | Margit Juhasz, MD, Clinical Research Fellow, University of California, Irvine |
ClinicalTrials.gov Identifier: | NCT03376581 |
Other Study ID Numbers: |
2016-3239 |
First Posted: | December 18, 2017 Key Record Dates |
Last Update Posted: | February 22, 2019 |
Last Verified: | February 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Alopecia Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical |